BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today reported strong revenue growth for the quarter ending June 30, 2008. Anika continued to strengthen its global position in joint health therapies with the European launch of its single-injection osteoarthritis product, MONOVISC™, for the relief of knee pain as well as the further domestic and international penetration of its flagship joint health product, ORTHOVISC®. The Company also recently partnered with Artes Medical to market and distribute its cosmetic dermal filler, ELEVESS™, in the United States.
